European Biotech Acquisition Corp. Units
EBACU
EBACU was delisted on the 2nd of March, 2023.
0 hedge funds and large institutions have $0 invested in European Biotech Acquisition Corp. Units in 2023 Q1 according to their latest regulatory filings, with 0 funds opening new positions, 0 increasing their positions, 0 reducing their positions, and 11 closing their positions.
100% less funds holding
Funds holding: 11 → 0 (-11)
100% less capital invested
Capital invested by funds: $8M → $0 (-$8M)
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 11
Top Buyers
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
-$2.01M |
| 2 |
Bank of Montreal
Toronto,
Ontario, Canada
|
-$1.78M |
| 3 |
Jane Street
New York
|
-$1.47M |
| 4 |
HF
HRT Financial
New York
|
-$755K |
| 5 |
Walleye Capital
New York
|
-$733K |
EBACU Hedge Fund Activity: Q1 2023 in Review
0 of the 6,285 institutional investors tracked by Wall St. Rank reported a position in European Biotech Acquisition Corp. Units (EBACU) for Q1 2023, worth a combined $0 — down 100% from $8M a quarter earlier.
Sellers outnumbered buyers: 11 funds closed out of EBACU and 0 opened new positions — a net loss of 11 holders — while 0 trimmed existing stakes and 0 added.
The largest seller was Millennium Management, exiting entirely with an estimated $2.01M sold.
- 0 institutional investors held European Biotech Acquisition Corp. Units (EBACU) as of Q1 2023, down from 11 in Q4 2022.
- Funds reported $0 of European Biotech Acquisition Corp. Units stock for Q1 2023, down 100% quarter-over-quarter.
- 0 funds opened new European Biotech Acquisition Corp. Units positions in Q1 2023 and 11 closed out, a net change of -11 holders.
- The largest European Biotech Acquisition Corp. Units seller in Q1 2023 was Millennium Management, an estimated $2.01M sold.
Based on aggregated 13F filings for Q1 2023.